MCLA-145

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMCLA-145
Drug Alias NameMCLA-145
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsProgrammed death-ligand 1 agonists
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursLymphoma, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte CorpMerus Nv
China Registration ClassN/A

Develop Information

Active CompaniesIncyte CorpMerus Nv
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma, B-Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A